GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Chimerix Inc (NAS:CMRX) » Definitions » Financial Strength

Chimerix (Chimerix) Financial Strength

: 6 (As of Dec. 2023)
View and export this data going back to 2013. Start your Free Trial

Chimerix has the Financial Strength Rank of 6.

GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is based on these factors:

1. The debt burden that the company has as measured by its Interest Coverage (current year). The higher, the better.
2. Debt to revenue ratio. The lower, the better.
3. Altman Z-Score.

GuruFocus does not calculate Chimerix's interest coverage with the available data. Chimerix's debt to revenue ratio for the quarter that ended in Dec. 2023 was 81.38. As of today, Chimerix's Altman Z-Score is -3.11.


Competitive Comparison

For the Biotechnology subindustry, Chimerix's Financial Strength, along with its competitors' market caps and Financial Strength data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Chimerix Financial Strength Distribution

For the Biotechnology industry and Healthcare sector, Chimerix's Financial Strength distribution charts can be found below:

* The bar in red indicates where Chimerix's Financial Strength falls into.



Chimerix Financial Strength Calculation

GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is based on these factors

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

1. The debt burden that the company has as measured by its Interest Coverage (current year). The higher, the better.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:

Chimerix's Interest Expense for the months ended in Dec. 2023 was $0.00 Mil. Its Operating Income for the months ended in Dec. 2023 was $-20.81 Mil. And its Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $1.30 Mil.

Chimerix's Interest Coverage for the quarter that ended in Dec. 2023 is

GuruFocus does not calculate Chimerix's interest coverage with the available data.

The higher the ratio, the stronger the company's financial strength is.

Good Sign:

Ben Graham prefers companies' interest coverage to be at least 5. Chimerix Inc has enough cash to cover all of its debt. Its financial situation is stable.

2. Debt to revenue ratio. The lower, the better.

Chimerix's Debt to Revenue Ratio for the quarter that ended in Dec. 2023 is

Debt to Revenue Ratio=Total Debt (Q: Dec. 2023 ) / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(0 + 1.302) / 0.016
=81.38

3. Altman Z-Score.

Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.

The zones of discrimination were as such:

When Z-Score is less than 1.81, it is in Distress Zones.
When Z-Score is greater than 2.99, it is in Safe Zones.
When Z-Score is between 1.81 and 2.99, it is in Grey Zones.

Chimerix has a Z-score of -3.11, indicating it is in Distress Zones. This implies bankrupcy possibility in the next two years.

Warning Sign:

Altman Z-score of -3.11 is in distress zone. This implies bankruptcy possibility in the next two years.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Chimerix  (NAS:CMRX) Financial Strength Explanation

The maximum rank is 10. Companies with rank 7 or higher will be unlikely to fall into distressed situations. Companies with rank of 3 or less are likely in financial distress.

Chimerix has the Financial Strength Rank of 6.


Chimerix Financial Strength Related Terms

Thank you for viewing the detailed overview of Chimerix's Financial Strength provided by GuruFocus.com. Please click on the following links to see related term pages.


Chimerix (Chimerix) Business Description

Traded in Other Exchanges
Address
2505 Meridian Parkway, Suite 100, Durham, NC, USA, 27713
Chimerix Inc. is a biopharmaceutical company based in the United States that engages in the research, development, and commercialization of medicines. Its portfolio includes treatment for acute myeloid leukemia (or AML) and antiviral treatment for smallpox. The company generates revenue through license agreements and a federal contract with the U.S. Biomedical Advanced Research and Development Authority (BARDA) for research and advanced development of drugs to treat various human diseases. The company operates only in one business segment namely pharmaceuticals.
Executives
Fred A Middleton director 400 SOUTH EL CAMINO REAL STE 1200, SAN MATEO CA 94402-1708
David Jakeman officer: Principal Accounting Officer C/O CHIMERIX, INC.,, 2505 MERIDIAN PARKWAY, SUITE 100, DURHAM NC 27713
Michael A. Sherman director, officer: Chief Executive Officer 3000 KENT AVE STE A1-100, WEST LAFAYETTE IN 47906
Martha J Demski director 7770 REGENTS ROAD SUITE 113-505, SAN DIEGO CA 92122
Robert J. Meyer director 2505 MERIDIAN PARKWAY, C/O CHIMERIX, INC, SUITE 100, DURHAM NC 27713
Michael T. Andriole officer: Chief Business Officer C/O ENDOCYTE, INC., 3000 KENT AVENUE, SUITE A1-100, WEST LAFAYETTE IN 47906
Cantex Pharmaceuticals, Inc. 10 percent owner 1792 BELL TOWER LANE, SUITE 222, WESTON FL 33326
Victoria Vakiener director C/O EPIZYME, INC., 400 TECHNOLOGY SQUARE, CAMBRIDGE MA 02139
Allen S. Melemed officer: Chief Medical Officer C/O CHIMERIX, INC., 2505 MERIDIAN PARKWAY, SUITE 100, DURHAM NC 27713
Pratik S Multani director C/O FATE THERAPEUTICS, INC., 3535 GENERAL ATOMICS COURT, SUITE 200, SAN DIEGO CA 92121
William Garrett Nichols officer: Chief Medical Officer C/O CANDEL THERAPEUTICS, INC., 117 KENDRICK ST SUITE 450, NEEDHAM MA 02494
Michael Albert Alrutz officer: Principal Executive Officer 2530 MERIDIAN PARKWAY, 2ND FLOOR, DURHAM NC 27713
M Michelle Berrey officer: Chief Medical Officer 303A COLLEGE ROAD EAST, PRINCETON NJ 08450
Ernest Mario director 20 FAIRMOUNT AVENUE, P.O. BOX 445, CHATHAM NJ 07928
Ed Greissing director 2505 MERIDIAN PARKWAY, C/O CHIMERIX, INC, SUITE 100, DURHAM NC 27713